Our Chairs Invite You To Join!
Following the great success of the virtual International Lung Cancer Summit (ILCS), we look forward to welcoming you to the 4th edition of this interactive hybrid meeting. Similar to recent years, the ILCS will showcase the latest discoveries and advances performed towards the treatment of lung cancer. The conference will leverage digital channels to provide exceptional outreach and opportunities for delegates from Medical Offices, Universities and Institutes to interact with world-class Medical Oncologists and Industry Professionals working in the field of lung cancer treatment and research.
The ILCS constitutes an ideal platform to share knowledge and seamless treatment procedures with our local and international speakers from the USA, Spain, Ireland, Israel, South Africa, Austria and Switzerland.
Solange Peters, MD-PhD
Solange Peters, MD-PhD, is Professor and chair of Medical Oncology as well as the Thoracic Malignancies programme in the department of oncology at Lausanne University Hospital, Switzerland. She has authored numerous peer-reviewed manuscripts and book chapters, and serves as deputy editor of the Journal of Thoracic Oncology, and on the editorial board of several other oncology journals. Professor Peters is active in the educational programs of the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC), notably working as the current editor of the ESMO lung cancer clinical practice guidelines. She is the Chair of ESMO Women for Oncology Committee, and she is the youngest ESMO President ever, for a mandate in 2020-2021. She was also a member of the IASLC board of directors, and acts as vice president of the Swiss Group for Clinical Cancer Research lung group. She received both her doctorate in medicine and PhD from Lausanne University Hospital, Switzerland. After completing her clinical education in medical oncology and molecular biology in Switzerland and Italy, Professor Peters has specialized in thoracic tumors, lung cancer, and pleural tumors.
Alfredo Addeo, MD
Alfredo Addeo, MD, is a Consultant Medical Oncologist at the University Hospital of Geneva, Switzerland. He is the author of numerous national and international peer-reviewed publications in renowned scientific journals, including first- and last-author publications in the Journal of Clinical Oncology, Annals of Oncology and Lancet Oncology. He has acted as a reviewer for several international scientific journals, including Journal of Thoracic Oncology and JAMA Oncology, and is an associate editor for Frontiers in Thoracic Oncology and guest editor for Precision Cancer Medicine. Dr. Addeo is an active ESMO member and a member of the EORTC lung group. He actively participates in ETOP (European Thoracic Oncology Platform) and SAKK (the Swiss Group for Clinical Cancer Research) and is a researcher and co-investigator of several national and international studies.
View the Photo Gallery
CME-Accredited
This meeting is accredited and CME-certified! Add this event to your calendar by selecting your calendar and download your certificate of attendance during the conference.
Swiss Society of Medical Oncology: 5 credit points
European Accreditation Council for Continuing Medical Education (EACCME): 4 credit points
Our Faculty
Jordi Remón
Gustave Roussy,
Villejuif, France
Jarushka Naidoo
Beaumont Hospital
Dublin, Ireland
Sandip Patel
UC Moores Cancer Center,
San Diego, USA
Alessandra Curioni
Cantonal Hospital
Fribourg, Switzerland
Stephen V. Liu
Georgetown Lombardi Ca. Center,
DC, USA
Noemi Reguart
Hospital Clinic
Barcelona, Spain
Wolf Janthur
Cantonal Hospital
Aarau, Switzerland
Sabina Berezowska
University Hospital
Lausanne, Switzerland
Sze Wai Chan
Sandton Oncology Centre
Johannesburg, South Africa
Jair Bar
Chaim Sheba Medical Center
Tel Aviv, Israel
Our Program
Recordings will be available as of 8th October
10.00
Welcome by Chairs
Solange Peters & Alfredo Addeo
10.02
The power of pathology: biomarkers and targets we are testing today
Sabina Berezowska (Switzerland)
10.20
The many faces of EGFR mutations: each a different target
Alessandra Curioni (Switzerland)
10.45
ALK: old known with new expanded therapeutic options
Sze-Wai Chan (South Africa)
11.15
Open discussion & coffee break
11.30
Drugging the undruggables: the advent of KRAS and HER2 in NSCLC
Jair Bar (Israel)
11.50
METex14 and RET: important oncogenic factors for our treatment decision
Jordi Remón (France)
14.00
Immunotherapies in good companionship: where do combination therapies make sense in advanced NSCLC – and where not?
Jarushka Naidoo (Ireland)
14.30
DEBATE:
OS vs. DFS in early NSCLC
Disease free survival is an adequate endpoint for immuno- and targeted therapies in adjuvant NSCLC
Noemi Reguart (Spain)
14.45
DEBATE:
OS vs. DFS in early NSCLC
OS is the only meaningful endpoint – also for adjuvant therapies
Wolf-Dieter Janthur (Switzerland)
15.00
Open discussion & coffee break
15.20
The path of immunotherapies to early NSCLC: my choice in stage I -III
Sandip Patel (USA)
15.50
Small Cell Lung Cancer: what are our options for SCLC in 1st and 2nd line today?
Stephen V. Liu (USA)
16.20
Do we follow our own commitments that we take away from congresses?
Panel Discussion With All
Our Sponsors
The Intl. Lung Cancer Summit 2022 is supported by our partners, with no influence on the content:
